Search

Your search keyword '"Heublein S"' showing total 182 results
Start Over Author "Heublein S"
182 results on '"Heublein S"'

1. Thyronamine regulation of TAAR1 expression in breast cancer cells and investigation of its influence on viability and migration

Author

Tremmel E, Hofmann S, Kuhn C, Heidegger H, Heublein S, Hermelink K, Wuerstlein R, Harbeck N, Mayr D, Mahner S, Ditsch N, Jeschke U, and Vattai A

Subjects
breast cancer, TAAR1, 3-Iodothyronamine, tetrac, MCF7, T47D, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Eileen Tremmel,1 Simone Hofmann,1 Christina Kuhn,1 Helene Heidegger,1 Sabine Heublein,2 Kerstin Hermelink,1 Rachel Wuerstlein,1 Nadia Harbeck,1 Doris Mayr,3 Sven Mahner,1 Nina Ditsch,1 Udo Jeschke,1 Aurelia Vattai1 1Breast Center, Department of Gynecology and Obstetrics and CCC Munich, University of Munich (LMU), 81377 Munich, Germany; 2Department of Gynecology and Obstetrics, University of Heidelberg, 69120 Heidelberg, Germany; 3Department of Pathology, Ludwig-Maximilians University of Munich, 81337 Munich, Germany Objectives: A correlation exists between breast cancer and thyroid disorders, which are common in elderly women. Thyroid hormones are degraded into trace amines, which can bind to the G-protein-coupled receptor trace amine-associated receptor 1 (TAAR1) and thereby activate it. The transformation of thyroid hormones into trace amines is carried out by the ornithine decarboxylase. Previously, we showed that TAAR1 overexpression (IRS ≥6) was associated with a significantly longer OS in primary breast cancer patients during a long-term follow-up of up to 14 years. Aim of the present study was to analyze the regulation of TAAR1 in breast cancer cell lines and the influence of triiodothyronine (T3), thyronamines, and tetraiodothyroacetic acid (Tetrac) on the expression of TAAR1 in breast cancer cells. Methods: The effect of T3, thyronamines, and Tetrac on the expression of TAAR1 in breast cancer cell lines MCF-7 and T47D was analyzed via PCR and Western blot. A MTT assay was performed to test the metabolic cell viability. A scratch assay was performed to analyze cell migration. Results: Stimulation of MCF-7 cells with 10 nM 3-iodothyronamine (T1AM) significantly increased TAAR1 protein expression (P=0.008). In T47D cells, TAAR1 expression was significantly upregulated after the addition of 10 µg/mL estradiol to 10 nM T1AM (P=0.008). A significant (P=0.028) reduction in MCF-7 cell viability through the incubation with T1AM could be detected. Cell migration of MCF cells was significantly reduced through incubation with 10 nM T1AM. Conclusion: A significant upregulation of TAAR1 induced by stimulation with T1AM may be a sign for an increased decarboxylation of thyroid hormones in breast cancer cells. In addition, there seems to be an influence of estradiol for the T1AM-induced upregulation of TAAR1 in T47D cells. TAAR1-related cell transduction mechanisms seem to be an interesting target for endocrine treatment options of breast cancer patients. Keywords: breast cancer, TAAR1, 3-iodothyronamine, Tetrac, MCF7, T47D

Published
2019

3. COGNITION: a prospective precision oncology trial for patients with early breast cancer at high risk following neoadjuvant chemotherapy

Author

Pixberg, C., Zapatka, M., Hlevnjak, M., Benedetto, S., Suppelna, J.P., Heil, J., Smetanay, K., Michel, L., Fremd, C., Körber, V., Rübsam, M., Buschhorn, L., Heublein, S., Schäfgen, B., Golatta, M., Gomez, C., von Au, A., Wallwiener, M., Wolf, S., Dikow, N., Schaaf, C., Gutjahr, E., Allgäuer, M., Stenzinger, A., Pfütze, K., Kirsten, R., Hübschmann, D., Sinn, H.-P., Jäger, D., Trumpp, A., Schlenk, R., Höfer, T., Thewes, V., Schneeweiss, A., and Lichter, P.

Published
2022
Full Text
View/download PDF

4. CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Author

Kang, E-Y, Weir, A, Meagher, NS, Farrington, K, Nelson, GS, Ghatage, P, Lee, C-H, Riggan, MJ, Bolithon, A, Popovic, G, Leung, B, Tang, K, Lambie, N, Millstein, J, Alsop, J, Anglesio, MS, Ataseven, B, Barlow, E, Beckmann, MW, Berger, J, Bisinotto, C, Boesmueller, H, Boros, J, Brand, AH, Brooks-Wilson, A, Brucker, SY, Carney, ME, Casablanca, Y, Cazorla-Jimenez, A, Cohen, PA, Conrads, TP, Cook, LS, Coulson, P, Courtney-Brooks, M, Cramer, DW, Crowe, P, Cunningham, JM, Cybulski, C, Darcy, KM, El-Bahrawy, MA, Elishaev, E, Erber, R, Farrell, R, Fereday, S, Fischer, A, Garcia, MJ, Gayther, SA, Gentry-Maharaj, A, Gilks, CB, Grube, M, Harnett, PR, Harrington, SP, Harter, P, Hartmann, A, Hecht, JL, Heikaus, S, Hein, A, Heitz, F, Hendley, J, Hernandez, BY, Hernando Polo, S, Heublein, S, Hirasawa, A, Hogdall, E, Hogdall, CK, Horlings, HM, Huntsman, DG, Huzarski, T, Jewell, A, Jimenez-Linan, M, Jones, ME, Kaufmann, SH, Kennedy, CJ, Khabele, D, Kommoss, FKF, Kruitwagen, RFPM, Lambrechts, D, Le, ND, Lener, M, Lester, J, Leung, Y, Linder, A, Loverix, L, Lubinski, J, Madan, R, Maxwell, GL, Modugno, F, Neuhausen, SL, Olawaiye, A, Olbrecht, S, Orsulic, S, Palacios, J, Pearce, CL, Pike, MC, Quinn, CM, Mohan, GR, Rodriguez-Antona, C, Ruebner, M, Ryan, A, Salfinger, SG, Sasamoto, N, Schildkraut, JM, Schoemaker, MJ, Shah, M, Sharma, R, Shvetsov, YB, Singh, N, Sonke, GS, Steele, L, Stewart, CJR, Sundfeldt, K, Swerdlow, AJ, Talhouk, A, Tan, A, Taylor, SE, Terry, KL, Toloczko, A, Traficante, N, Van de Vijver, KK, van der Aa, MA, Van Gorp, T, Van Nieuwenhuysen, E, Van-Wagensveld, L, Vergote, I, Vierkant, RA, Wang, C, Wilkens, LR, Winham, SJ, Wu, AH, Benitez, J, Berchuck, A, Candido Dos Reis, FJ, DeFazio, A, Fasching, PA, Goode, EL, Goodman, MT, Gronwald, J, Karlan, BY, Kommoss, S, Menon, U, Sinn, H-P, Staebler, A, Brenton, JD, Bowtell, DD, Pharoah, PDP, Ramus, SJ, Kobel, M, Kang, E-Y, Weir, A, Meagher, NS, Farrington, K, Nelson, GS, Ghatage, P, Lee, C-H, Riggan, MJ, Bolithon, A, Popovic, G, Leung, B, Tang, K, Lambie, N, Millstein, J, Alsop, J, Anglesio, MS, Ataseven, B, Barlow, E, Beckmann, MW, Berger, J, Bisinotto, C, Boesmueller, H, Boros, J, Brand, AH, Brooks-Wilson, A, Brucker, SY, Carney, ME, Casablanca, Y, Cazorla-Jimenez, A, Cohen, PA, Conrads, TP, Cook, LS, Coulson, P, Courtney-Brooks, M, Cramer, DW, Crowe, P, Cunningham, JM, Cybulski, C, Darcy, KM, El-Bahrawy, MA, Elishaev, E, Erber, R, Farrell, R, Fereday, S, Fischer, A, Garcia, MJ, Gayther, SA, Gentry-Maharaj, A, Gilks, CB, Grube, M, Harnett, PR, Harrington, SP, Harter, P, Hartmann, A, Hecht, JL, Heikaus, S, Hein, A, Heitz, F, Hendley, J, Hernandez, BY, Hernando Polo, S, Heublein, S, Hirasawa, A, Hogdall, E, Hogdall, CK, Horlings, HM, Huntsman, DG, Huzarski, T, Jewell, A, Jimenez-Linan, M, Jones, ME, Kaufmann, SH, Kennedy, CJ, Khabele, D, Kommoss, FKF, Kruitwagen, RFPM, Lambrechts, D, Le, ND, Lener, M, Lester, J, Leung, Y, Linder, A, Loverix, L, Lubinski, J, Madan, R, Maxwell, GL, Modugno, F, Neuhausen, SL, Olawaiye, A, Olbrecht, S, Orsulic, S, Palacios, J, Pearce, CL, Pike, MC, Quinn, CM, Mohan, GR, Rodriguez-Antona, C, Ruebner, M, Ryan, A, Salfinger, SG, Sasamoto, N, Schildkraut, JM, Schoemaker, MJ, Shah, M, Sharma, R, Shvetsov, YB, Singh, N, Sonke, GS, Steele, L, Stewart, CJR, Sundfeldt, K, Swerdlow, AJ, Talhouk, A, Tan, A, Taylor, SE, Terry, KL, Toloczko, A, Traficante, N, Van de Vijver, KK, van der Aa, MA, Van Gorp, T, Van Nieuwenhuysen, E, Van-Wagensveld, L, Vergote, I, Vierkant, RA, Wang, C, Wilkens, LR, Winham, SJ, Wu, AH, Benitez, J, Berchuck, A, Candido Dos Reis, FJ, DeFazio, A, Fasching, PA, Goode, EL, Goodman, MT, Gronwald, J, Karlan, BY, Kommoss, S, Menon, U, Sinn, H-P, Staebler, A, Brenton, JD, Bowtell, DD, Pharoah, PDP, Ramus, SJ, and Kobel, M

Abstract

BACKGROUND: Cyclin E1 (CCNE1) is a potential predictive marker and therapeutic target in tubo-ovarian high-grade serous carcinoma (HGSC). Smaller studies have revealed unfavorable associations for CCNE1 amplification and CCNE1 overexpression with survival, but to date no large-scale, histotype-specific validation has been performed. The hypothesis was that high-level amplification of CCNE1 and CCNE1 overexpression, as well as a combination of the two, are linked to shorter overall survival in HGSC. METHODS: Within the Ovarian Tumor Tissue Analysis consortium, amplification status and protein level in 3029 HGSC cases and mRNA expression in 2419 samples were investigated. RESULTS: High-level amplification (>8 copies by chromogenic in situ hybridization) was found in 8.6% of HGSC and overexpression (>60% with at least 5% demonstrating strong intensity by immunohistochemistry) was found in 22.4%. CCNE1 high-level amplification and overexpression both were linked to shorter overall survival in multivariate survival analysis adjusted for age and stage, with hazard stratification by study (hazard ratio [HR], 1.26; 95% CI, 1.08-1.47, p = .034, and HR, 1.18; 95% CI, 1.05-1.32, p = .015, respectively). This was also true for cases with combined high-level amplification/overexpression (HR, 1.26; 95% CI, 1.09-1.47, p = .033). CCNE1 mRNA expression was not associated with overall survival (HR, 1.00 per 1-SD increase; 95% CI, 0.94-1.06; p = .58). CCNE1 high-level amplification is mutually exclusive with the presence of germline BRCA1/2 pathogenic variants and shows an inverse association to RB1 loss. CONCLUSION: This study provides large-scale validation that CCNE1 high-level amplification is associated with shorter survival, supporting its utility as a prognostic biomarker in HGSC.

Published
2023

5. Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Author

Weir, A, Kang, E-Y, Meagher, NS, Nelson, GS, Ghatage, P, Lee, C-H, Riggan, MJ, Gentry-Maharaj, A, Ryan, A, Singh, N, Widschwendter, M, Alsop, J, Anglesio, MS, Beckmann, MW, Berger, J, Bisinotto, C, Boros, J, Brand, AH, Brenton, JD, Brooks-Wilson, A, Carney, ME, Cunningham, JM, Cushing-Haugen, KL, Cybulski, C, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Paz-Ares, L, Gayarre, J, Gilks, BC, Grube, M, Harnett, PR, Harris, HR, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Heublein, S, Huang, Y, Huzarski, T, Jakubowska, A, Jimenez-Linan, M, Kennedy, CJ, Kommoss, FKF, Koziak, JM, Kraemer, B, Le, ND, Lesnock, J, Lester, J, Lubinski, J, Menkiszak, J, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Robles-Diaz, L, Ruebner, M, Shah, M, Sharma, R, Shvetsov, YB, Steed, H, Talhouk, A, Taylor, SE, Traficante, N, Vierkant, RA, Wang, C, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, Candido dos Reis, FJ, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Garcia, MJ, Goode, EL, Goodman, MT, Gronwald, J, Huntsman, DG, Karlan, BY, Kommoss, S, Modugno, F, Schildkraut, JM, Sinn, H-P, Staebler, A, Kelemen, LE, Ford, CE, Menon, U, Pharoah, PDP, Koebel, M, Ramus, SJ, Bowtell, D, Brand, A, Harnett, P, Weir, A, Kang, E-Y, Meagher, NS, Nelson, GS, Ghatage, P, Lee, C-H, Riggan, MJ, Gentry-Maharaj, A, Ryan, A, Singh, N, Widschwendter, M, Alsop, J, Anglesio, MS, Beckmann, MW, Berger, J, Bisinotto, C, Boros, J, Brand, AH, Brenton, JD, Brooks-Wilson, A, Carney, ME, Cunningham, JM, Cushing-Haugen, KL, Cybulski, C, Elishaev, E, Erber, R, Fereday, S, Fischer, A, Paz-Ares, L, Gayarre, J, Gilks, BC, Grube, M, Harnett, PR, Harris, HR, Hartmann, A, Hein, A, Hendley, J, Hernandez, BY, Heublein, S, Huang, Y, Huzarski, T, Jakubowska, A, Jimenez-Linan, M, Kennedy, CJ, Kommoss, FKF, Koziak, JM, Kraemer, B, Le, ND, Lesnock, J, Lester, J, Lubinski, J, Menkiszak, J, Ney, B, Olawaiye, A, Orsulic, S, Osorio, A, Robles-Diaz, L, Ruebner, M, Shah, M, Sharma, R, Shvetsov, YB, Steed, H, Talhouk, A, Taylor, SE, Traficante, N, Vierkant, RA, Wang, C, Wilkens, LR, Winham, SJ, Benitez, J, Berchuck, A, Bowtell, DD, Candido dos Reis, FJ, Cook, LS, DeFazio, A, Doherty, JA, Fasching, PA, Garcia, MJ, Goode, EL, Goodman, MT, Gronwald, J, Huntsman, DG, Karlan, BY, Kommoss, S, Modugno, F, Schildkraut, JM, Sinn, H-P, Staebler, A, Kelemen, LE, Ford, CE, Menon, U, Pharoah, PDP, Koebel, M, Ramus, SJ, Bowtell, D, Brand, A, and Harnett, P

Abstract

BACKGROUND: Recently, we showed a >60% difference in 5-year survival for patients with tubo-ovarian high-grade serous carcinoma (HGSC) when stratified by a 101-gene mRNA expression prognostic signature. Given the varied patient outcomes, this study aimed to translate prognostic mRNA markers into protein expression assays by immunohistochemistry and validate their survival association in HGSC. METHODS: Two prognostic genes, FOXJ1 and GMNN, were selected based on high-quality antibodies, correlation with protein expression and variation in immunohistochemical scores in a preliminary cohort (n = 134 and n = 80, respectively). Six thousand four hundred and thirty-four (FOXJ1) and 5470 (GMNN) formalin-fixed, paraffin-embedded ovarian neoplasms (4634 and 4185 HGSC, respectively) represented on tissue microarrays from the Ovarian Tumor Tissue Analysis consortium underwent immunohistochemical staining and scoring, then univariate and multivariate survival analysis. RESULTS: Consistent with mRNA, FOXJ1 protein expression exhibited a linear, increasing association with improved overall survival in HGSC patients. Women with >50% expression had the most favourable outcomes (HR = 0.78, 95% CI 0.67-0.91, p < 0.0001). GMNN protein expression was not significantly associated with overall HSGC patient survival. However, HGSCs with >35% GMNN expression showed a trend for better outcomes, though this was not significant. CONCLUSION: We provide foundational evidence for the prognostic value of FOXJ1 in HGSC, validating the prior mRNA-based prognostic association by immunohistochemistry.

Published
2023

8. Risiko für eine pelvine Metastasierung und Stellenwert der pelvinen Lymphonodektomie bei Patientinnen mit nodal-positivem Vulvakarzinom – Ergebnisse der AGO-VOP.2/QS Vulva Studie

Author

Jaeger, A, additional, Hampl, M, additional, Zu Eulenburg, C, additional, Prieske, K, additional, Hambrecht, J, additional, Fuerst, S, additional, Klapdor, R, additional, Heublein, S, additional, Gass, P, additional, Rohner, A, additional, Canzler, U, additional, Becker, S, additional, Bommert, M, additional, Bauerschlag, D, additional, Denecke, A, additional, Hanker, L, additional, Runnebaum, I, additional, Forner, DM, additional, Schochter, F, additional, Klar, M, additional, Schwab, R, additional, Koepke, M, additional, Kalder, M, additional, Hantschmann, P, additional, Ratiu, D, additional, Denschlag, D, additional, Schroeder, W, additional, Tuschy, B, additional, Baumann, K, additional, Mustea, A, additional, Soergel, P, additional, Bronger, H, additional, Bauerschmitz, G, additional, Kosse, J, additional, Koch, MC, additional, Ignatov, A, additional, Sehouli, J, additional, Dannecker, C, additional, Mahner, S, additional, and Woelber, L, additional

Published
2022
Full Text
View/download PDF

9. 561P When to treat the pelvis in node-positive vulvar cancer: Results from the AGO-VOP.2 QS vulva study

Author

Hampl, M., primary, Jaeger, A., additional, Eulenburg, C., additional, Prieske, K., additional, Hambrecht, J., additional, Fuerst, S., additional, Klapdor, R., additional, Heublein, S., additional, Gass, P., additional, Rohner, A., additional, Canzler, U., additional, Becker, S., additional, Bommert, M., additional, Bauerschlag, D., additional, Denecke, A., additional, Hanker, L., additional, Sehouli, J., additional, Dannecker, C., additional, Mahner, S., additional, and Woelber, L., additional

Published
2022
Full Text
View/download PDF

11. 358P Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa

Author

Fehm, T.N., Schochter, F., Rack, B., Wimberger, P., Paluchowski, M. Banys, Neubauer, H., Wiesmueller, L., Meier-Stiegen, F., Fasching, P.A., Blohmer, J-U., Hartkopf, A.D., Heublein, S., Huober, J., Riethdorf, S., Pantel, K., Schneeweiss, A., Friedl, T.W.P., Mueller, V., and Janni, W.

Published
2024
Full Text
View/download PDF

14. Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8(+) TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas

Author

Heinze, K, Nazeran, TM, Lee, S, Kramer, P, Cairns, ES, Chiu, DS, Leung, SCY, Kang, EY, Meagher, NS, Kennedy, CJ, Boros, J, Kommoss, F, Vollert, H-W, Heitze, F, du Bois, A, Harter, P, Grube, M, Kraemer, B, Staebler, A, Kommoss, FKF, Heublein, S, Sinn, H-P, Singh, N, Laslavic, A, Elishaev, E, Olawaiye, A, Moysich, K, Modugno, F, Sharma, R, Brand, AH, Harnett, PR, DeFazio, A, Fortner, RT, Lubinski, J, Lener, M, Toloczko-Grabarek, A, Cybulski, C, Gronwald, H, Gronwald, J, Coulson, P, El-Bahrawy, MA, Jones, ME, Schoemaker, MJ, Swerdlow, AJ, Gorringe, KL, Campbell, I, Cook, L, Gayther, SA, Carney, ME, Shvetsov, YB, Hernandez, BY, Wilkens, LR, Goodman, MT, Mateoiu, C, Linder, A, Sundfeldt, K, Kelemen, LE, Gentry-Maharaj, A, Widschwendter, M, Menon, U, Bolton, KL, Alsop, J, Shah, M, Jimenez-Linan, M, Pharoah, PDP, Brenton, JD, Cushing-Haugen, KL, Harris, HR, Doherty, JA, Gilks, B, Ghatage, P, Huntsman, DG, Nelson, GS, Tinker, A, Lee, C-H, Goode, EL, Nelson, BH, Ramus, SJ, Kommoss, S, Talhouk, A, Kobel, M, Anglesio, MS, Heinze, K, Nazeran, TM, Lee, S, Kramer, P, Cairns, ES, Chiu, DS, Leung, SCY, Kang, EY, Meagher, NS, Kennedy, CJ, Boros, J, Kommoss, F, Vollert, H-W, Heitze, F, du Bois, A, Harter, P, Grube, M, Kraemer, B, Staebler, A, Kommoss, FKF, Heublein, S, Sinn, H-P, Singh, N, Laslavic, A, Elishaev, E, Olawaiye, A, Moysich, K, Modugno, F, Sharma, R, Brand, AH, Harnett, PR, DeFazio, A, Fortner, RT, Lubinski, J, Lener, M, Toloczko-Grabarek, A, Cybulski, C, Gronwald, H, Gronwald, J, Coulson, P, El-Bahrawy, MA, Jones, ME, Schoemaker, MJ, Swerdlow, AJ, Gorringe, KL, Campbell, I, Cook, L, Gayther, SA, Carney, ME, Shvetsov, YB, Hernandez, BY, Wilkens, LR, Goodman, MT, Mateoiu, C, Linder, A, Sundfeldt, K, Kelemen, LE, Gentry-Maharaj, A, Widschwendter, M, Menon, U, Bolton, KL, Alsop, J, Shah, M, Jimenez-Linan, M, Pharoah, PDP, Brenton, JD, Cushing-Haugen, KL, Harris, HR, Doherty, JA, Gilks, B, Ghatage, P, Huntsman, DG, Nelson, GS, Tinker, A, Lee, C-H, Goode, EL, Nelson, BH, Ramus, SJ, Kommoss, S, Talhouk, A, Kobel, M, and Anglesio, MS

Published
2022

15. Risk of pelvic metastasis and significance of pelvic lymphadenectomy in patients with node-positive vulvar cancer - results of the AGO-VOP.2/QS vulva study

Author

Jaeger, A., Hampl, M., Zu Eulenburg, C., Prieske, K., Hambrecht, J., Fuerst, S., Klapdor, R., Heublein, S., Gass, P., Rohner, A., Canzler, U., Becker, S., Bommert, M., Bauerschlag, D., Denecke, A., Hanker, L., Runnebaum, I, Forner, D. M., Schochter, F., Klar, M., Schwab, R., Koepke, M., Kalder, M., Hantschmann, P., Ratiu, D., Denschlag, D., Schroeder, W., Tuschy, B., Baumann, K., Mustea, A., Soergel, P., Bronger, H., Bauerschmitz, G., Kosse, J., Koch, M. C., Ignatov, A., Sehouli, J., Dannecker, C., Mahner, S., Woelber, L., Jaeger, A., Hampl, M., Zu Eulenburg, C., Prieske, K., Hambrecht, J., Fuerst, S., Klapdor, R., Heublein, S., Gass, P., Rohner, A., Canzler, U., Becker, S., Bommert, M., Bauerschlag, D., Denecke, A., Hanker, L., Runnebaum, I, Forner, D. M., Schochter, F., Klar, M., Schwab, R., Koepke, M., Kalder, M., Hantschmann, P., Ratiu, D., Denschlag, D., Schroeder, W., Tuschy, B., Baumann, K., Mustea, A., Soergel, P., Bronger, H., Bauerschmitz, G., Kosse, J., Koch, M. C., Ignatov, A., Sehouli, J., Dannecker, C., Mahner, S., and Woelber, L.

Published
2022

17. 382 Molecular classification of endometrial carcinoma substantially changing risk-assessment: Results from a european multicentre initiative

Author

Kommoss, S, primary, Grube, M, additional, Knoll, K, additional, Lum, A, additional, Brambs, C, additional, Pauly, N, additional, Kommoss, F, additional, Heublein, S, additional, Battista, M, additional, Mittelstadt, S, additional, Rohner, A, additional, Preaetorius, T, additional, Hasenburg, A, additional, Ataseven, B, additional, Talhouk, A, additional, Diebold, J, additional, Zeimet, AG, additional, Staebler, A, additional, and Mcalpine, J, additional

Published
2021
Full Text
View/download PDF

19. CAPTOR-BC – Umfassende Analyse der räumlichen, zeitlichen und molekularen Muster zur Vorhersage der Wirksamkeit und Resistenz von Ribociclib bei Patientinnen mit fortgeschrittenem Brustkrebs.

Author

Fasching, P. A., Brucker, S. Y., Hübner, H., Thewes, V., Volmer, L. L., Hartkopf, A., Engler, T., Hack, C. C., Juhasz-Boess, I., Kolberg, H.-C., Lüftner, D., Lux, M. P., Schmid, M., Tesch, H., Thill, M., Untch, M., Link, T., Heublein, S., Nel, I., and Neubauer, H.

Published
2024
Full Text
View/download PDF

21. 454 Study in progress: international retrospective study on lymphadenectomy in endometrioid ovarian carcinoma patients with early stage disease (LEOPARD)

Author

Krämer, P, primary, Grube, M, additional, Renno, T, additional, Brar, H, additional, McAlpine, JN, additional, de Kroon, CD, additional, Heitz, F, additional, Heublein, S, additional, Manchanda, R, additional, Plante, M, additional, Bachvarov, D, additional, Zeimet, AG, additional, Schmalfeldt, B, additional, Wimberger, P, additional, Lampe, B, additional, Trillsch, F, additional, Grimm, C, additional, Staebler, A, additional, Kommoss, F, additional, Talhouk, A, additional, Köbel, M, additional, Anglesio, MS, additional, and Kommoss, S, additional

Published
2020
Full Text
View/download PDF

22. Anwendung der molekularen Risikostratifikation des Endometriums auf das endometrioide Ovarialkarzinom- eine retrospektive, internationale Multizenterstudie

Author

Heitz, F, additional, Krämer, P, additional, Talhouk, A, additional, MA, Brett, additional, DS, Chiu, additional, ES, Cairns, additional, Scheunhage, D, additional, RF, Hammond, additional, Senz, J, additional, Leung, S, additional, Hartkopf, A, additional, Krämer, B, additional, Brucker, S, additional, du Bois, A, additional, Harter, P, additional, FK, Kommoss, additional, Heublein, S, additional, Kommoss, F, additional, JN, McAlpine, additional, Singh, N, additional, Bosse, T, additional, Köbel, M, additional, MS, Anglesio, additional, Staebler, A, additional, and Kommoss, S, additional

Published
2020
Full Text
View/download PDF

33. Prevalence of thyroid dysfunction in metastasized breast cancer

Author

Heublein, S, additional, Katsikogianni, F, additional, Sinn, HP, additional, Fasching, PA, additional, Belleville, E, additional, Wallwiener, M, additional, Schütz, F, additional, Jäger, D, additional, Sohn, C, additional, Mavratzas, A, additional, Marmé, F, additional, and Schneeweiss, A, additional

Published
2019
Full Text
View/download PDF

43. Detection and characterisation of disseminated tumour cells in bone marrow of breast cancer patients by immunostaining of Her-2 and MUC-1 in combination with Thomsen-Friedenreich (CD176)

Author

Andergassen, U., Kölbl, A. C., Zebisch, M., Heublein, S., Hutter, S., Matthias Ilmer, Schindlbeck, C., Friese, K., and Jeschke, U.

Subjects
6 - Ciencias aplicadas::61 - Medicina [CDU], Bone marrow, Thomsen-Friedenreich-antigen, DTCs, Imunostaining
Abstract

Disseminated tumour cells (DTCs) in the bone marrow derive from many primary tumours, such as breast cancer. Their mere existence hints to present or future metastasis and implicates a worse prognosis for the patient. DTCs may possess different characteristics in comparison to the primary tumour due to events like Epithelial-Mesenchymal-Transition. Therefore these cells might be able to survive chemotherapy and cause relapses of the disease at a later point. We aimed to detect and further characterise DTCs by an immunostaining approach with three different antigen markers (Her-2, MUC-1 and TF, also known as CD176). For that reason, bone marrow of 41 breast cancer patients was obtained during surgery; DTCs were enriched by density gradient centrifugation and cytospins were prepared. After fixation, immunofluorescent double-stainings were carried out with antibodies against CD176 in combination with HER-2 or MUC-1. Cells co-expressing two antigens were found in all staining combinations (Her-2 and CD176: 46.14%; MUC-1 and CD176: 18.15% of all cases). Cells that stained for a single antigen only were also found (Her-2: 36.86%; MUC-1: 34.45%; CD176: 29.65% of all cases). Significant correlations between the stainings of all markers could be shown (p

Published
2014

47. Expression of nuclear hormone receptors in ovarian cancer

Author

Göß, C, primary, Heublein, S, additional, Sattler, C, additional, Kolben, T, additional, Kolben, TM, additional, Burgmann, M, additional, Mayr, D, additional, Gallwas, J, additional, Burges, A, additional, Mahner, S, additional, Jeschke, U, additional, and Ditsch, N, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results